Dopamine agonists for preventing ovarian hyperstimulation syndrome

Tang, Huilin; Mourad, Selma; Wang, Aihua; Zhai, Suodi; Hart, Roger

doi:10.1002/14651858.cd008605.pub4

Cited by 18 publications

(11 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the introduction of cabergoline as a prophylactic strategy, severe ovaries have been reported [35]. In a paper, Tang et al (2016) stated that dopamine agonists reduce the incidence of moderate to severe OHSS in women at high risk for this complication compared with placebo or no treatment [36].…”

Section: Results and Dissectionmentioning

confidence: 99%

Untitled

2022

J. Med. Chem. Sci.

View full text Add to dashboard Cite

Background: Polycystic ovarian syndrome (PCO) is among the most common reasons for infertility in women of reproductive age. Objective: to examine two pharmaceutical regimens for infertile women with polycystic ovarian syndrome. Method: In this randomized clinical trial, 60 infertile women with PCO were randomly assigned into two arms, each having 30 subjects. The first arm received Clomiphene citrate (CC) followed by letrozole. The second arm received letrozole followed by cabergoline. Following the procedures, outcomes of biochemical pregnancy and incidence of the complications were recorded along with other baseline characteristics and laboratory data. Results: Concerning age, weight, height, and BMI, both arms were matched. In terms of follicle quantity and size, as well as endometrial thickness, with no statistical differences among the study arms, although the cabergolineletrozole regimen demonstrated a considerably higher success rate in the treatment of infertility. The endometrial examination revealed three-layered and transparent endometrium in both arms, although it was statistically more common in the letrozole-cabergoline arm (P = 0.001). The successful pregnancy was achieved in 9 cases (30%) in the first arm and 7 (23.3%) in the second arm (P=0.54), with no significant difference in adverse maternal events. Conclusion:The letrozole-cabergoline regimen appears to be more successful in inducing ovulation in infertile women with PCOs. Other trials should be conducted over longer periods of time and at varied dosages to provide a more exact evaluation of its effect.

show abstract

Section: Results and Dissectionmentioning

confidence: 99%

Untitled

2022

J. Med. Chem. Sci.

View full text Add to dashboard Cite

show abstract

“…The application of progesterone is better than injections of choriogonadotropin mostly due to the less frequent OHSS [33]. In the cases of hyperprolactinemia the addition of dopamine agonists gave positive effect [34]. It has been also recommended to perform myomectomy in cases deforming uterus cavity [35], hysteroscopic incision of intrauterine adhesions [36], and laparoscopic elimination of the fallopian tube hydrosalpinxes [37].The very controversial subject in the strategy of an improvement of an endometrial receptivity is the endometrial scratching /injury/ in the cycle before embryo-transfer [38].There are data suggesting that such scratching might cause the increase of chance for pregnancy in cases of RIF, but there are also information that endometrial scratching is without any positive effect [40].…”

Section: Strategy For the Improvement Of Endometrial Receptivitymentioning

confidence: 99%

Implantation of embryos. The way for the improvement of the cumulative life birth rate (CLBR) in the assisted reproductive technology (ART)

Szamatowicz

2023

Ginekol Pol

View full text Add to dashboard Cite

Despite the willingness, humans belong to the species with the limited procreation possibilities. Infertility affects about 15 % of population is the very important subject for the reproductive medicine. An assisted reproductive technology (ART) offers the significant chance for the infertile couples, but it does not give the guarantee for the pregnancy and for the birth of a healthy child. The implantation of embryo, despite numerous trials and attempts, remain the last barrier in the assisted reproduction technologies; thus, the endometrial receptivity becomes the subject of permanent interest. In this review we have tried to present various methods of improvement of an endometrial receptivity with the conclusion that we still wait for the valuable prognostic factor in the treatment of infertility by ART which could predict the chance for the birth of a healthy child.

show abstract

“…It is believed that hCG enhances the vascular permeability, which in turn causes ascites and various other complications by activating the vascular endothelial growth factor (VEGF) system, leading to the development of OHSS 79,80 . Studies have proved the effect of bromocriptine in reducing the severity of OHSS among the high risk patients 81,82 . It is considered to act by reversing the elevated vascular permeability and angiogenic activities of vascular permeability factor/VEGF in hyper stimulated patients of OHSS through inhibition of phosphorylation of VEGF receptor‐2 (VEGFR‐2) and therefore, interfering VEGA/VEGA‐2 signalling without distressing the outcome of ART 83,84 .…”

Section: Pharmacological Significance Of Bromocriptinementioning

confidence: 99%

“…79,80 Studies have proved the effect of bromocriptine in reducing the severity of OHSS among the high risk patients. 81,82 It is considered to act by reversing the elevated vascular permeability and angiogenic activities of vascular permeability factor/VEGF in hyper stimulated patients of OHSS through inhibition of phosphorylation of VEGF receptor-2 (VEGFR-2) and therefore, interfering VEGA/VEGA-2 signalling without distressing the outcome of ART. 83,84 Rectal administration of bromocriptine at 2.5 mg dose starting on the day of ovulation is preferred in patients with OHSS.…”

Section: Ovarian Hyperstimulation Syndromementioning

confidence: 99%

Bromocriptine therapy: Review of mechanism of action, safety and tolerability

Naz

Malik

Riaz

et al. 2022

Clin Exp Pharma Physio

View full text Add to dashboard Cite

Bromocriptine is a sympatholytic dopamine D2 receptor agonist with remarkable bioactivities. It has been used clinically as a prescription drug for more than 30 years to treat hyperprolactinemia associated conditions, Parkinson's disease, acromegaly, prolactinomas and other pituitary hormone dependent adenomas and recently, diabetes mellitus as well as various other disorders. Long‐term treatment with bromocriptine has minimal or no harmful effects on renal, hepatic, cardiac or hematologic functions. This review article was planned to study the hypothetical and proposed mechanism of action as well as provide a brief discussion about its safety issues and tolerability. Bromocriptine represents an attractive option with high efficacy and safety profile for hyperprolactinemia‐associated conditions, acromegaly, parkinsonism, type 2 diabetes mellitus and various other diseases in a variety of dosage forms for best possible beneficial effects. It appeared to be an effective and safe addition to the pharmacopoeia of drugs for the treatment of a vast variety of diseases as monotherapy or in combination with other drugs.

show abstract

Dopamine agonists for preventing ovarian hyperstimulation syndrome

Abstract: Editorial group: Cochrane Gynaecology and Fertility Group. Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 4, 2021.

Cited by 18 publications

References 84 publications

Untitled

Untitled

Implantation of embryos. The way for the improvement of the cumulative life birth rate (CLBR) in the assisted reproductive technology (ART)

Bromocriptine therapy: Review of mechanism of action, safety and tolerability

Contact Info

Product

Resources

About